Auditory Late Effects of Childhood Cancer Therapy: A Report From the Children's Oncology Group Article

Full Text via DOI: 10.1542/peds.2009-1597 PMID: 20194279 Web of Science: 000276239600065

Cited authors

  • Grewal, Satkiran; Merchant, Thomas; Reymond, Renee; McInerney, Maryrose; Hodge, Cathy; Shearer, Patricia


  • Children treated for malignancies may be at risk for early-or delayedonset hearing loss that can affect learning, communication, school performance, social interaction, and overall quality of life. Survivors at particular risk include those treated with platinum compounds (cisplatin and/or carboplatin) for neuroblastoma, hepatoblastoma, osteosarcoma, or germ-cell tumors and/or those treated with radiation that affects the ear at doses of >30 Gy for pediatric head and neck tumors. The aims of the Auditory/Hearing Late Effects Task Force of the Children's Oncology Group in this report were to (1) review ototoxicity resulting from childhood cancer therapy including platinum compounds (cisplatin and carboplatin) and radiation, (2) describe briefly cochlear pathophysiology and genetics of cisplatin-related hearing loss, (3) explain the impact of hearing loss resulting from chemotherapy and radiation, and (4) offer recommendations regarding evaluation and management of pediatric patients who are at risk for treatment-related hearing loss. A questionnaire is included as a tool to assist pediatricians in assessment. Pediatrics 2010; 125: e938-e950

Publication date

  • 2010

Published in

International Standard Serial Number (ISSN)

  • 0031-4005

Start page

  • E938

End page

  • E950


  • 125


  • 4